Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response

Louis Philippe Boulet, Kenneth R. Chapman, Johanne Côté, Sanjay Kalra, Rajesh Bhagat, Veronica A. Swystun, Michel Laviolette, Laura D. Cleland, Francine Deschesnes, John Q. Su, Arthur Devault, Robert B. Fick, Donald W. Cockcroft

Research output: Contribution to journalArticle

340 Citations (Scopus)

Abstract

Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers of airway hyperresponsiveness and airway inflammation. The effect of anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration of allergen causing a 15% fall in FEV1 (allergen PC15) during the allergen-induced early asthmatic response (EAR) was assessed in a multicenter, randomized, double-blind, parallel group study. Ten of 11 allergic asthmatic subjects randomized to receive intravenous rhuMAb-E25, 2 mg/kg on study day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70 completed the study; nine received intravenous placebo. The allergen PC15 was measured on Days -1, 27, 55, and 77 and methacholine PC20 on Days -2, 42, and 76. rhuMAb-25 was well tolerated and only one patient (active group) was withdrawn because of a generalized urticarial rash after the first dose. Compared with baseline values (Day -1), the median allergen PC15 on Days 27, 55, and 77 were increased by 2.3, 2.2, and 2.7 doubling doses (Δ log PC15/0.3) respectively with rhuMAb-E25 and -0.3, +0.1, and -0.8 doubling doses with placebo (p0.002). Methacholine PC20 improved slightly after rhuMAb-E25, this change becoming statistically significant on Day 76 (p < 0.05); no change was observed in the placebo group. Mean serum-free IgE fell by 89% after rhuMAb-E25 while there was no significant change after placebo. The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma.

Original languageEnglish (US)
Pages (from-to)1835-1840
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume155
Issue number6
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Antibodies, Monoclonal, Humanized
Allergens
Placebos
Methacholine Chloride
Immunoglobulin E
Asthma
Anti-Allergic Agents
anti-IgE antibodies
Exanthema
Inflammation
Serum

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. / Boulet, Louis Philippe; Chapman, Kenneth R.; Côté, Johanne; Kalra, Sanjay; Bhagat, Rajesh; Swystun, Veronica A.; Laviolette, Michel; Cleland, Laura D.; Deschesnes, Francine; Su, John Q.; Devault, Arthur; Fick, Robert B.; Cockcroft, Donald W.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 6, 01.01.1997, p. 1835-1840.

Research output: Contribution to journalArticle

Boulet, LP, Chapman, KR, Côté, J, Kalra, S, Bhagat, R, Swystun, VA, Laviolette, M, Cleland, LD, Deschesnes, F, Su, JQ, Devault, A, Fick, RB & Cockcroft, DW 1997, 'Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response', American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 6, pp. 1835-1840. https://doi.org/10.1164/ajrccm.155.6.9196083
Boulet, Louis Philippe ; Chapman, Kenneth R. ; Côté, Johanne ; Kalra, Sanjay ; Bhagat, Rajesh ; Swystun, Veronica A. ; Laviolette, Michel ; Cleland, Laura D. ; Deschesnes, Francine ; Su, John Q. ; Devault, Arthur ; Fick, Robert B. ; Cockcroft, Donald W. / Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. In: American Journal of Respiratory and Critical Care Medicine. 1997 ; Vol. 155, No. 6. pp. 1835-1840.
@article{33a513ba8ba24482be6bf57ff36f294d,
title = "Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response",
abstract = "Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers of airway hyperresponsiveness and airway inflammation. The effect of anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration of allergen causing a 15{\%} fall in FEV1 (allergen PC15) during the allergen-induced early asthmatic response (EAR) was assessed in a multicenter, randomized, double-blind, parallel group study. Ten of 11 allergic asthmatic subjects randomized to receive intravenous rhuMAb-E25, 2 mg/kg on study day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70 completed the study; nine received intravenous placebo. The allergen PC15 was measured on Days -1, 27, 55, and 77 and methacholine PC20 on Days -2, 42, and 76. rhuMAb-25 was well tolerated and only one patient (active group) was withdrawn because of a generalized urticarial rash after the first dose. Compared with baseline values (Day -1), the median allergen PC15 on Days 27, 55, and 77 were increased by 2.3, 2.2, and 2.7 doubling doses (Δ log PC15/0.3) respectively with rhuMAb-E25 and -0.3, +0.1, and -0.8 doubling doses with placebo (p0.002). Methacholine PC20 improved slightly after rhuMAb-E25, this change becoming statistically significant on Day 76 (p < 0.05); no change was observed in the placebo group. Mean serum-free IgE fell by 89{\%} after rhuMAb-E25 while there was no significant change after placebo. The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma.",
author = "Boulet, {Louis Philippe} and Chapman, {Kenneth R.} and Johanne C{\^o}t{\'e} and Sanjay Kalra and Rajesh Bhagat and Swystun, {Veronica A.} and Michel Laviolette and Cleland, {Laura D.} and Francine Deschesnes and Su, {John Q.} and Arthur Devault and Fick, {Robert B.} and Cockcroft, {Donald W.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1164/ajrccm.155.6.9196083",
language = "English (US)",
volume = "155",
pages = "1835--1840",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response

AU - Boulet, Louis Philippe

AU - Chapman, Kenneth R.

AU - Côté, Johanne

AU - Kalra, Sanjay

AU - Bhagat, Rajesh

AU - Swystun, Veronica A.

AU - Laviolette, Michel

AU - Cleland, Laura D.

AU - Deschesnes, Francine

AU - Su, John Q.

AU - Devault, Arthur

AU - Fick, Robert B.

AU - Cockcroft, Donald W.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers of airway hyperresponsiveness and airway inflammation. The effect of anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration of allergen causing a 15% fall in FEV1 (allergen PC15) during the allergen-induced early asthmatic response (EAR) was assessed in a multicenter, randomized, double-blind, parallel group study. Ten of 11 allergic asthmatic subjects randomized to receive intravenous rhuMAb-E25, 2 mg/kg on study day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70 completed the study; nine received intravenous placebo. The allergen PC15 was measured on Days -1, 27, 55, and 77 and methacholine PC20 on Days -2, 42, and 76. rhuMAb-25 was well tolerated and only one patient (active group) was withdrawn because of a generalized urticarial rash after the first dose. Compared with baseline values (Day -1), the median allergen PC15 on Days 27, 55, and 77 were increased by 2.3, 2.2, and 2.7 doubling doses (Δ log PC15/0.3) respectively with rhuMAb-E25 and -0.3, +0.1, and -0.8 doubling doses with placebo (p0.002). Methacholine PC20 improved slightly after rhuMAb-E25, this change becoming statistically significant on Day 76 (p < 0.05); no change was observed in the placebo group. Mean serum-free IgE fell by 89% after rhuMAb-E25 while there was no significant change after placebo. The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma.

AB - Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers of airway hyperresponsiveness and airway inflammation. The effect of anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration of allergen causing a 15% fall in FEV1 (allergen PC15) during the allergen-induced early asthmatic response (EAR) was assessed in a multicenter, randomized, double-blind, parallel group study. Ten of 11 allergic asthmatic subjects randomized to receive intravenous rhuMAb-E25, 2 mg/kg on study day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70 completed the study; nine received intravenous placebo. The allergen PC15 was measured on Days -1, 27, 55, and 77 and methacholine PC20 on Days -2, 42, and 76. rhuMAb-25 was well tolerated and only one patient (active group) was withdrawn because of a generalized urticarial rash after the first dose. Compared with baseline values (Day -1), the median allergen PC15 on Days 27, 55, and 77 were increased by 2.3, 2.2, and 2.7 doubling doses (Δ log PC15/0.3) respectively with rhuMAb-E25 and -0.3, +0.1, and -0.8 doubling doses with placebo (p0.002). Methacholine PC20 improved slightly after rhuMAb-E25, this change becoming statistically significant on Day 76 (p < 0.05); no change was observed in the placebo group. Mean serum-free IgE fell by 89% after rhuMAb-E25 while there was no significant change after placebo. The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma.

UR - http://www.scopus.com/inward/record.url?scp=8244226656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244226656&partnerID=8YFLogxK

U2 - 10.1164/ajrccm.155.6.9196083

DO - 10.1164/ajrccm.155.6.9196083

M3 - Article

C2 - 9196083

AN - SCOPUS:8244226656

VL - 155

SP - 1835

EP - 1840

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -